Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IMUX

Immunic Inc

Dec 11 • 04:00PM ET

1.21

Dollar change -0.03
Percentage change -2.42	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE IOVA AGEN KPTI ADAP MCRB AFMD IMTX ALDX ZLAB

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	3.02%	Shs Outstand	90.08M	Perf Week	-3.20%
Market Cap	109.00M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	3.32%	Shs Float	87.36M	Perf Month	-1.63%
Income	-96.90M	PEG	-	EPS next Q	-0.24	Inst Own	62.53%	Short Float	4.80%	Perf Quarter	-18.79%
Sales	0.00M	P/S	-	EPS this Y	54.30%	Inst Trans	14.62%	Short Ratio	4.65	Perf Half Y	-3.97%
Book/sh	0.46	P/B	2.64	EPS next Y	21.19%	ROA	-147.12%	Short Interest	4.19M	Perf Year	2.54%
Cash/sh	0.66	P/C	1.85	EPS next 5Y	15.50%	ROE	-216.24%	52W Range	0.97 - 2.11	Perf YTD	-19.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	31.12%	ROI	-234.04%	52W High	-42.65%	Beta	1.86
Dividend TTM	-	Quick Ratio	2.71	Sales past 5Y	0.00%	Gross Margin	-	52W Low	24.74%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	2.71	EPS Y/Y TTM	61.97%	Oper. Margin	-	RSI (14)	47.86	Volatility	6.84% 7.99%
Employees	77	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.79
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	52.90%	Payout	-	Rel Volume	0.73	Prev Close	1.24
Sales Surprise	-100.00%	EPS Surprise	-9.89%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	901.25K	Price	1.21
SMA20	2.24%	SMA50	-7.33%	SMA200	-9.24%	Trades		Volume	658,471	Change	-2.42%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-24	Initiated	H.C. Wainwright	Buy	$10
Sep-09-24	Resumed	Leerink Partners	Outperform	$5
Aug-27-24	Initiated	B. Riley Securities	Buy	$6
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Sep-19-22	Resumed	H.C. Wainwright	Buy	$26
Apr-15-21	Initiated	Aegis Capital	Buy	$55
Mar-24-21	Initiated	JMP Securities	Mkt Outperform	$55
Oct-02-20	Initiated	SVB Leerink	Outperform	$45
Aug-26-20	Initiated	Piper Sandler	Overweight	$71
Aug-07-20	Resumed	ROTH Capital	Buy	$64
Jul-20-20	Initiated	BMO Capital Markets	Outperform	$40
Jun-05-20	Initiated	Wedbush	Outperform	$59
May-11-20	Initiated	H.C. Wainwright	Buy	$45
Mar-25-20	Initiated	ROTH Capital	Buy	$44
Jul-11-19	Initiated	Chardan Capital Markets	Buy	$40

Show Previous Ratings

Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESSWIRE) -9.29%
Nov-26-24 06:30AM	Immunic, Inc. to Participate in Investor Conference in December (PR Newswire)
Nov-14-24 06:35AM	Immunic announces publication of IMU-856 data (TipRanks) -6.84%
Nov-13-24 06:30AM	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (PR Newswire)
Nov-09-24 08:00AM	Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
06:41AM	Loading…
Nov-07-24 06:41AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Oct-31-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (PR Newswire)
Oct-29-24 06:30AM	Immunic to Participate in Industry, Scientific and Investor Conferences in November (PR Newswire)
Oct-22-24 06:30AM	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (PR Newswire) -9.68%
Oct-09-24 05:31PM	Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... (GuruFocus.com) -6.67%
Sep-18-24 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (PR Newswire) +11.18%
Sep-04-24 06:30AM	Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (PR Newswire)
Aug-28-24 06:30AM	Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (PR Newswire)
Aug-08-24 06:34AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) +14.53%
06:30AM	Loading…
06:30AM	Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-01-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (PR Newswire)
Jul-24-24 06:30AM	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (PR Newswire) -5.48%
Jul-09-24 06:30AM	Immunic Appoints Jason Tardio as Chief Operating Officer and President (PR Newswire) +7.76%
May-30-24 07:03AM	Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day (News Direct)
May-28-24 06:30AM	Immunic to Participate in Industry and Scientific Conferences in June (PR Newswire)
May-23-24 06:00AM	Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying (InvestorPlace)
May-20-24 10:00AM	Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day (News Direct)
May-17-24 02:35PM	Immunic chief medical officer discusses promising treatments to mark World IBD Day (News Direct)
May-16-24 05:54PM	Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day (News Direct)
May-09-24 10:23AM	Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:58AM	Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones (News Direct)
May-08-24 06:36AM	Immunic: Q1 Earnings Snapshot (Associated Press Finance) -7.97%
06:30AM	Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-06-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)
10:02AM	Loading…
May-01-24 10:02AM	Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal (News Direct)
06:30AM	Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update (PR Newswire)
Apr-30-24 06:30AM	Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology & Neuroinflammation (PR Newswire)
Apr-29-24 11:11AM	Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role (News Direct)
Apr-04-24 06:30AM	Immunic to Host MS R&D Day and Participate in Investor Conferences in April (PR Newswire)
Mar-21-24 12:14PM	Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month (News Direct)
11:37AM	Immunic secures key patent, boosting MS drug exclusivity and global IP strategy (News Direct)
Mar-20-24 06:30AM	Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States (PR Newswire)
Mar-08-24 06:53AM	Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024 (News Direct)
Mar-07-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
Feb-29-24 06:30AM	Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 (PR Newswire)
Feb-23-24 09:02PM	Immunic Inc (IMUX) Reports Year-End 2023 Financial Results (GuruFocus.com)
11:04AM	Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 10:59AM	Immunic reports successful 2023 and prepares for key 2025 milestones (News Direct)
06:30AM	Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update (PR Newswire)
Feb-15-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update (PR Newswire)
Feb-01-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-05-24 06:35AM	Immunic Highlights 2023 Accomplishments and Upcoming Milestones (PR Newswire)
06:30AM	Immunic, Inc. Announces Private Placement of up to $240 Million (PR Newswire)
Nov-21-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis (PR Newswire)
Nov-14-23 01:25PM	Immunic focusing on business development during Q4 (News Direct)
06:36AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 06:30AM	Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update (PR Newswire)
Nov-02-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts (PR Newswire)
Oct-26-23 06:30AM	Immunic to Participate in Scientific and Industry Conferences in November (PR Newswire)
Oct-24-23 07:51AM	Immunic CSO hails "great" progress with MS program (News Direct)
Oct-16-23 06:30AM	Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-15-23 06:30AM	Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-11-23 06:30AM	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting (PR Newswire)
05:15AM	Immunic "super excited" about latest PMS trial data (News Direct)
Oct-10-23 09:07AM	Immunic's investors appeased by interim biomarker data from phase 2 MS trial (FierceBiotech.com) -13.84%
Oct-09-23 04:01PM	Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
Oct-04-23 06:30AM	Immunic to Participate in Scientific Conferences in October (PR Newswire)
Sep-06-23 06:30AM	Immunic to Participate in Industry and Investor Conferences in September (PR Newswire)
Aug-21-23 08:00AM	Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment (News Direct)
Aug-17-23 06:30AM	Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
Aug-07-23 09:50AM	Immunic CEO says Q2 results "couldn't be better" (News Direct) -5.97%
Aug-03-23 06:47AM	Immunic: Q2 Earnings Snapshot (AP Finance)
06:30AM	Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Aug-01-23 06:30AM	Immunic to Participate in Investor and Scientific Conferences in August (PR Newswire)
Jul-28-23 04:19PM	10 Best Rated Penny Stocks to Buy According to Analysts (Insider Monkey) +16.18%
Jul-27-23 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire) -6.42%
Jul-25-23 08:00AM	Immunic Inc eyeing "big step" for multiple sclerosis patients (News Direct)
Jul-24-23 10:33AM	With 50% stake, Immunic, Inc. (NASDAQ:IMUX) seems to have captured institutional investors' interest (Simply Wall St.)
Jun-29-23 06:30AM	Immunic to Participate in Scientific and Investor Conferences in July (PR Newswire) +18.56%
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +11.89%
09:11AM	Pleasing Signs As A Number Of Insiders Buy Immunic Stock (Simply Wall St.)
Jun-26-23 03:44PM	Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases (News Direct)
May-31-23 07:42AM	Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis (News Direct) -5.17%
May-30-23 06:30AM	Immunic to Participate in Scientific and Investor Conferences in June (PR Newswire)
May-17-23 10:00AM	Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program (News Direct) +6.47%
06:30AM	Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis (PR Newswire)
May-16-23 01:07PM	Immunic Inc set to bring relief with encouraging results (News Direct)
May-11-23 06:40AM	Immunic: Q1 Earnings Snapshot (AP Finance)
06:30AM	Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-09-23 06:30AM	Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update (PR Newswire)
May-06-23 06:30AM	Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action (PR Newswire)
May-04-23 06:30AM	Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders (PR Newswire) -5.78%
Apr-27-23 06:30AM	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. (PR Newswire)
Apr-26-23 06:30AM	Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)
Apr-13-23 08:00AM	Immunic gets a "positive surprise" from lead asset trial (News Direct) +10.14%
Apr-06-23 02:10PM	Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data (Zacks) -10.32%
Apr-05-23 12:30PM	After Positive Data In Ulcerative Colitis Study, Immunic Prioritizes Vidofludimus Calcium Program With One More Candidate (Benzinga) +6.16%
06:30AM	Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis (PR Newswire)
Mar-02-23 06:30AM	Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
Feb-28-23 05:22AM	Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-26-23 08:23AM	Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 06:30AM	Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update (PR Newswire)
Feb-22-23 06:30AM	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 (PR Newswire)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rudick Richard Alan	Director	Nov 12 '24	Buy	1.15	87,300	100,369	87,300	Nov 13 02:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMUX

Immunic Inc

Upgrade your FINVIZ experience